Antiangiogenic strategies in breast cancer management

被引：22

作者：

Giovannini, Monica ^{[1
]}

Aldrighetti, Daniela ^{[1
]}

Zucchinelli, Patrizia ^{[1
]}

Belli, Carmen ^{[1
]}

Villa, Eugenio ^{[1
]}

机构：

[1] Univ Hosp, San Raffaele Sci Inst, Dept Oncol, Med Oncol Unit, Milan, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2010年 / 76卷 / 01期

关键词：

Breast cancer angiogenesis; Antiangiogenic agents; Monoclonal antibodies; Tyrosin kinase inhibitors; Metronomic chemotherapy; Bisphosphonates; Hormonal therapy; COX-2; inhibitors; GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITOR; PHASE-II TRIAL; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; ENDOTHELIAL-CELL PROLIFERATION; BASEMENT-MEMBRANE COMPONENT; LAPATINIB PLUS CAPECITABINE; CARCINOMA IN-SITU; TUMOR ANGIOGENESIS; ESTROGEN-RECEPTOR;

D O I：

10.1016/j.critrevonc.2009.12.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Angiogenesis is considered one of the key mechanisms of tumour growth and survival. Therefore it represents an ideal pharmaceutical target. Many antiangiogenic agents have been developed so far in several solid tumours and also in breast cancer. Vascular endothelial growth factor (VEFG) is the main target and both monoclonal antibodies and small molecules belonging to the tyrosine kinase inhibitors directed against VEGF(R) have been developed. Some other therapeutic approaches have shown to exert some antiangiogenic activity, such as hormonal agents, metronomic chemotherapy, bisphosphonates and others. In this paper we provide an introduction of the current data supporting the angiogenesis in breast cancer and a review of the most relevant antiagiogenic therapies which have been investigated so far. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

引用

页码：13 / 35

页数：23

共 216 条

[1]

Abrams TJ, 2003, MOL CANCER THER, V2, P1011

[2] Incorporation of Antiangiogenic Therapies in the Treatment of Metastatic Breast Cancer [J].

Ademuyiwa, Foluso O. ;

Miller, Kathy D. .

CLINICAL BREAST CANCER, 2008, 8 :S151-S156

[3]

Ahlgren P, 2009, J CLIN ONCOL, V27

[4]

Albain K, 2002, BREAST CANCER RES TR, V76, pS33

[5] Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells [J].

Allegra, A. ;

Oteri, G. ;

Nastro, E. ;

Alonci, A. ;

Bellomo, G. ;

Del Fabro, V. ;

Quartarone, E. ;

Alati, C. ;

De Ponte, F. S. ;

Cicciu, D. ;

Musolino, C. .

HEMATOLOGICAL ONCOLOGY, 2007, 25 (04) :164-169

[6] Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer [J].

Altorki, NK ;

Keresztes, RS ;

Port, JL ;

Libby, MD ;

Korst, RJ ;

Flieder, DB ;

Ferrara, CA ;

Yankelevitz, DF ;

Subbaramaiah, K ;

Pasmantier, MW ;

Dannenberg, AJ .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) :2645-2650

[7]

[Anonymous], 29 ANN SAN ANT BREAS

[8] Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways [J].

Arbiser, JL ;

Moses, MA ;

Fernandez, CA ;

Ghiso, N ;

Cao, YH ;

Klauber, N ;

Frank, D ;

Brownlee, M ;

Flynn, E ;

Parangi, S ;

Byers, HR ;

Folkman, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (03) :861-866

[9] Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance [J].

Arpino, Grazia ;

Wiechmann, Lisa ;

Osborne, C. Kent ;

Schiff, Rachel .

ENDOCRINE REVIEWS, 2008, 29 (02) :217-233

[10] A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer [J].

Arteaga, Carlos L. ;

O'Neill, Anne ;

Moulder, Stacy L. ;

Pins, Michael ;

Sparano, Joseph A. ;

Sledge, George W. ;

Davidson, Nancy E. .

CLINICAL CANCER RESEARCH, 2008, 14 (19) :6277-6283

← 1 2 3 4 5 6 7 8 9 10 →